Search for a trial

A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Coformulated
quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in
Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient
(dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

This study has been transitioned to CTIS with ID 2022-502100-70-00 check the CTIS register for the current data. The aim of this research is:1. To test the safety of MK-1308A, MK-4280A, MK-7684A and MK 4830 + pembrolizumab against pembrolizumab as…